11C-索拉非尼与15O-H2O PET早期评估索拉非尼疗效
这项前瞻性探索性研究纳入8例晚期实体恶性肿瘤并需索拉非尼治疗的患者,在治疗前及治疗2周后行微剂量11C-索拉非尼和灌注15O-H2O动态PET扫描。主要目的是评估肿瘤11C-索拉非尼摄取能否预测治疗期间肿瘤活检样本中的索拉非尼浓度;结果显示不能预测。基线及第14天肿瘤11C-索拉非尼高积聚与较差预后相关,且与肿瘤灌注相关(Spearman相关系数=0.671,P=0.020);仅治疗14天后15O-H2O PET测得的肿瘤灌注下降与缓解相关,稳定疾病患者灌注下降56%±23%(均值±标准差),进展疾病患者为18%±32%。
要点
- 微剂量11C-索拉非尼PET不能预测治疗剂量后肿瘤内索拉非尼浓度。
- 基线及第14天肿瘤11C-索拉非尼高积聚与较差预后相关。
- 治疗14天后15O-H2O PET示肿瘤灌注下降与缓解相关。
核心结论
- 微剂量11C-索拉非尼PET不能预测治疗剂量后肿瘤内索拉非尼浓度。
- 肿瘤灌注下降与临床获益的关联值得进一步研究。
研究设计与样本
- 前瞻性探索性研究,纳入8例晚期实体恶性肿瘤且有索拉非尼治疗指征的患者。
- 治疗前及治疗2周后行微剂量11C-索拉非尼和灌注15O-H2O动态PET扫描。
主要发现
- 11C-索拉非尼PET结果不能预测治疗期间肿瘤活检样本中的索拉非尼浓度。
- 索拉非尼血浆和肿瘤浓度与临床结局无关。
- 基线和第14天肿瘤11C-索拉非尼高积聚与较差预后相关,并与肿瘤灌注相关(Spearman相关系数=0.671,P=0.020)。
- 治疗14天后15O-H2O PET测得的肿瘤灌注下降与缓解相关,稳定疾病患者下降56%±23%(均值±标准差),进展疾病患者下降18%±32%。
关键数值与推荐
- 主要目标:评估肿瘤11C-索拉非尼摄取是否预测治疗期间肿瘤活检样本中索拉非尼浓度(液相色谱串联质谱法测定)。
- 次要目标:确定11C-索拉非尼PET、15O-H2O PET灌注及治疗剂量后索拉非尼浓度与缓解的关联。
临床怎么用
- 微剂量11C-索拉非尼PET目前不适用于预测肿瘤内索拉非尼浓度。
- 15O-H2O PET测得的早期肿瘤灌注下降可能有助于提示索拉非尼治疗缓解,但需进一步验证。
局限性
- 探索性研究样本量小(8例),结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sorafenib leads to clinical benefit in a subgroup of patients, whereas all are exposed to potential toxicity. Currently, no predictive biomarkers are available. The purpose of this study was to evaluate whether 11C-sorafenib and 15O-H2O PET have potential to predict treatment efficacy. Methods: In this prospective exploratory study, 8 patients with advanced solid malignancies and an indication for sorafenib treatment were included. Microdose 11C-sorafenib and perfusion 15O-H2O dynamic PET scans were performed before and after 2 wk of sorafenib therapy. The main objective was to assess whether tumor 11C-sorafenib uptake predicts sorafenib concentrations during therapy in corresponding tumor biopsy samples measured with liquid chromatography tandem mass spectrometry. Secondary objectives included determining the association of 11C-sorafenib PET findings, perfusion 15O-H2O PET findings, and sorafenib concentrations after therapeutic dosing with response. Results:11C-sorafenib PET findings did not predict sorafenib concentrations in tumor biopsy samples during therapy. In addition, sorafenib plasma and tumor concentrations were not associated with clinical outcome in this exploratory study. Higher 11C-sorafenib accumulation in tumors at baseline and day 14 of treatment showed an association with poorer prognosis and correlated with tumor perfusion (Spearman correlation coefficient = 0.671, P = 0.020). Interestingly, a decrease in tumor perfusion measured with 15O-H2O PET after only 14 d of therapy showed an association with response, with a decrease in tumor perfusion of 56% ± 23% (mean ± SD) versus 18% ± 32% in patients with stable and progressive disease, respectively. Conclusion: Microdose 11C-sorafenib PET did not predict intratumoral sorafenib concentrations after therapeutic dosing, but the association between a decrease in tumor perfusion and clinical benefit warrants further investigation.
引用
- Mammatas LH, Yaqub M, Hendrikse NH, et al. 11C-Sorafenib and 15O-H2O PET for Early Evaluation of Sorafenib Therapy. J Nucl Med. 2020. PMID: 33127619. doi:10.2967/jnumed.120.251611
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。